Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome

Overview

Obstructive sleep apnea (OSA) is a highly prevalent chronic sleep disorder that affects 3% to 7% in middle aged individuals and increases with age. OSA has been identified as the most common secondary cause associated with resistant hypertension. There is evidence that compared with older patients, the risk of hypertension in OSA patients may be particularly pronounced in younger adult ones (less than 50 years). Traditionally, cardiovascular risk stratification in hypertensive patients was based on the average blood pressure (BP) measured in the clinic. Accumulated data has shown that target-organ damage is related not only to 24-h mean intra-arterial BP, but also to BP variability (BPV) in subjects with essential hypertension. Growing evidence demonstrated that BPV has considerable prognostic value for all-cause mortality and cardiovascular outcomes, independent of average BP. In addition, it has been found that hypoxia condition in pneumoconiosis patients was closely associated with exaggerated BPV in ambulatory BP. However, the selections of antihypertensive drugs remain yet not very clearly for hypertensive patients combined with OSA.

Full Title of Study: “The Study Was Approved by the Ethics Committee of Our Institution, Which is Accredited by the Office of Human Research Protection as an Institutional Review Board”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: June 2017

Detailed Description

Obstructive sleep apnea (OSA) is a highly prevalent chronic sleep disorder that affects 3% to 7% in middle aged individuals and increases with age. It is considered an important independent contributing factor for the development of hypertension, diabetes and heart rhythm disorders. The prevalence of arterial hypertension has been reported to reach 50% of patients with OSA. OSA has been identified as the most common secondary cause associated with resistant hypertension. There is evidence that compared with older patients, the risk of hypertension in OSA patients may be particularly pronounced in younger adult ones (less than 50 years). Traditionally, cardiovascular risk stratification in hypertensive patients was based on the average blood pressure (BP) measured in the clinic. Accumulated data has shown that target-organ damage is related not only to 24-h mean intra-arterial BP, but also to BP variability (BPV) in subjects with essential hypertension. Growing evidence demonstrated that BPV has considerable prognostic value for all-cause mortality and cardiovascular outcomes, independent of average BP. In addition, it has been found that hypoxia condition in pneumoconiosis patients was closely associated with exaggerated BPV in ambulatory BP. However, the selections of antihypertensive drugs remain yet not very clearly for hypertensive patients combined with OSA.

Interventions

  • Drug: Amlodipine
    • Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
  • Drug: metoprolol
    • Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.

Arms, Groups and Cohorts

  • Experimental: OSA-amlodipine
    • To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
  • Experimental: OSA-metoprolol
    • To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment

Clinical Trial Outcome Measures

Primary Measures

  • 24-hour Ambulatory Blood Pressure Monitoring
    • Time Frame: up to 3 years

Secondary Measures

  • 24-hour continuous ambulatory electrocardiography
    • Time Frame: up to 3 years
  • Ultrasonic echocardiography
    • Time Frame: up to 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Men aged between 18 and 75 included years old, and – Postmenopausal women who are no more than 75 years older. – Patients with essential mild to moderate uncomplicated hypertension (DBP<110mmHg and SBP<180mmHg measured with a validated automatic device in sitting position) after initiation or intensification of appropriate healthy lifestyle modification, – Without antihypertensive treatment in 2 weeks. Exclusion Criteria:

  • History of cerebrovascular disease: ischemic stroke, cerebral haemorrhage and TIA. – History of cardiovascular disease:unstable angina, myocardial infarction, coronary revascularization and congestive heart failure. – History of renal impairment. – History of Type I diabetes mellitus or Type II diabetes uncontrolled. – History of liver impairment. – History of alcoholism or drug abuse. – Known symptomatic orthostatic hypotension. – Contra-indications to treatment with investigate products.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • First Affiliated Hospital of Harbin Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Yue Li, PHD, 86-451-85555673, ly99ly@vip.163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.